A Precision Prescription: Updated Genetic Guidelines for Safer Thiopurine Use
The Clinical Pharmacogenetics Implementation Consortium (CPIC) has released its 2025 update on thiopurine dosing, a critical class of drugs used in conditions like leukemia and autoimmune disorders. The guideline provides refined recommendations for adjusting starting doses of medications like mercaptopurine, thioguanine, and azathioprine based on a patient’s genetic profile. It focuses on two key enzymes, thiopurine methyltransferase (TPMT) and Nudix hydrolase 15 (NUDT15), whose reduced or absent function due to genetic variants can lead to severe, life-threatening myelosuppression. This updated framework is essential for clinicians to personalize therapy, minimize adverse drug reactions, and improve patient outcomes across diverse global populations.
Why it might matter to you: For hematologists managing patients with leukemia or those undergoing stem cell transplantation, this guideline directly impacts clinical decision-making for chemotherapy and immunosuppression. It offers a concrete, evidence-based tool to prevent severe bone marrow toxicity, a major complication that can derail treatment and require supportive interventions like transfusion. Integrating this pharmacogenetic testing into standard practice represents a key step towards personalized hematology, potentially improving the safety and efficacy of foundational drug therapies.
Source →Stay curious. Stay informed — with Science Briefing.
Always double check the original article for accuracy.